| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
CYM50374 targets the S1P4 receptor, a G protein-coupled receptor involved in immune cell trafficking, lymphocyte egress, and inflammatory responses. It acts as a potent antagonist, blocking S1P4 signaling. This receptor is a member of the sphingosine-1-phosphate receptor family, which plays critical roles in the immune system.
|
|---|---|
| ln Vitro |
CYM50374 is a potent S1P4 antagonist with an IC50 of 34 nM. It selectively blocks S1P4 receptor signaling. The compound is used as a pharmacological tool to study the role of S1P4 in various biological processes, including immune cell trafficking and inflammation.
|
| ln Vivo |
In vivo activity data for CYM50374 is limited. As a potent and selective S1P4 antagonist, it is expected to modulate immune cell functions and inflammatory responses. The compound is used as a research tool to study the role of S1P4 in various disease models, including autoimmune and inflammatory conditions.
|
| Enzyme Assay |
CYM50374 is evaluated in cell-free receptor binding assays to determine its affinity and selectivity for S1P receptors. Radioligand binding displacement assays are performed using membrane preparations expressing S1P receptor subtypes. Competition binding experiments are conducted with increasing concentrations of CYM50374 and a fixed concentration of a labeled reference ligand.
|
| Cell Assay |
CYM50374 is assessed in cell-based functional assays to measure its antagonist activity at S1P4. Cells expressing S1P4 are treated with CYM50374, and receptor activity is measured by assessing downstream signaling pathways, such as GTPγS binding or calcium mobilization. IC50 values are determined to quantify the potency of receptor antagonism.
|
| Animal Protocol |
CYM50374 is administered in animal models to evaluate its effects on S1P4-mediated immune functions. However, specific animal study protocols are not extensively documented. The compound is typically formulated for in vivo administration using DMSO or other suitable vehicles.
|
| ADME/Pharmacokinetics |
CYM50374 has a molecular weight of 341.42 and a molecular formula of C19H19NO3S. It has a CAS number of 1314212-81-1. The compound should be stored as a powder at -20°C for long-term stability. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CYM50374. The compound is for research use only and is not intended for human therapeutic use. Its safety profile has not been extensively characterized in the available literature.
|
| References | |
| Additional Infomation |
CYM50374 is a novel and potent S1PR4 antagonist. It has a CAS number of 1314212-81-1. It is used as a pharmacological tool to study the role of S1P4 in immune cell trafficking, lymphocyte egress, and inflammatory responses. It is not approved for clinical use.
|
| Exact Mass |
341.1086
|
|---|---|
| CAS # |
1314212-81-1
|
| Appearance |
Typically exists as solid at room temperature
|
| Chemical Name |
5-(3-Methyl-thiophen-2-yl)-furan-2-carboxylic acid (4-hydroxymethyl-2,6-dimethyl-phenyl)-amide
|
| Synonyms |
CYM-50374 CYM 50374 CYM50374
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
